Browsing by Author "Mahave, Mauricio"

Now showing 1 - 5 of 5
  • Thumbnail Image
    Item
    A Chilean Blood Bank Network for COVID-19 Convalescent Plasma Apheresis
    (2020) Briones, José; Selma, Carolina; Villarroel, Franz; Caglevic, Christian; Mahave, Mauricio; Pereira Garcés, Jaime Ignacio; Chang RathKamp, Mayling Raquel; Nájera, Manuel; Yarado, Fernanda; Morales, Ricardo
  • Thumbnail Image
    Item
    Early Anti-SARS-CoV-2 Convalescent Plasma in Patients Admitted for COVID-19: A Randomized Phase II Clinical Trial
    (2020) Balcells, María Elvira ; Rojas, Luis ; Le Corre, Nicole ; Martínez-Valdebenito, Constanza ; Ceballos, María Elena ; Ferrés, Marcela ; Chang, Mayling ; Vizcaya, Cecilia ; Mondaca, Sebastián ; Huete, Álvaro ; Castro, Ricardo ; Sarmiento, Mauricio ; Villarroel, Luis ; Pizarro, Alejandra; Ross, Patricio ; Santander, Jaime ; Lara, Barbara ; Ferrada, Marcela ; Vargas-Salas, Sergio ; Beltrán-Pavez, Carolina ; Soto-Rifo, Ricardo ; Valiente-Echeverría, Fernando ; Caglevic, Christian ; Mahave, Mauricio ; Selman, Carolina ; Gazitúa, Raimundo ; Briones, José Luis ; Villarroel-Espindola, Franz ; Balmaceda, Carlos ; Espinoza, Manuel A. ; Pereira, Jaime ; Nervi, Bruno
  • Thumbnail Image
    Item
    Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial
    (2021) Balcells Marty, Maria Elvira; Rojas Orellana, Luis Esteban; Martínez Valdebenito, Constanza Pamela; Ceballos Valdivielso, María Elena Andrea; Ferrés Garrido, Marcela Viviana; Chang Rathkamp, Mayling Raquel; Vizcaya Altamirano, María Cecilia; Mondaca Contreras, Sebastián Patricio; Huete Garín, Isidro Álvaro; Castro López, Ricardo Adolfo; Sarmiento Maldonado, Mauricio; Villarroel Del Pino, Luis Antonio; Pizarro Ibáñez, Alejandra Valentina; Ross Pérez, Patricio Daniel; Santander Toro, Jaime Andrés; Lara Hernández, Bárbara Alejandra; Ferrada Koch, Marcela Patricia; Vargas Salas, Sergio Sebastián; Beltrán Pávez, Carolina; Soto Rifo, Ricardo; Valiente Echeverria, Fernando Andrés; Caglevic, Christian; Mahave, Mauricio; Selman Bravo, Carolina Antoniett; Gazitúa, Raimundo; Briones, José Luis; Villarroel Espíndola, Franz; Balmaceda Araque, Carlos Felipe; Espinoza Sepúlveda, Manuel Antonio; Pereira Garces, Jaime; Nervi Nattero, Bruno; Le Corre Perez, Monique Nicole
    Background: Convalescent plasma (CP), despite limited evidence on its efficacy, is being widely used as a compassionate therapy for hospitalized patients with COVID-19. We aimed to evaluate the efficacy and safety of early CP therapy in COVID-19 progression.", "Methods and findings", "The study was an open-label, single-center randomized clinical trial performed in an academic medical center in Santiago, Chile, from May 10, 2020, to July 18, 2020, with final follow-up until August 17, 2020. The trial included patients hospitalized within the first 7 days of COVID-19 symptom onset, presenting risk factors for illness progression and not on mechanical ventilation. The intervention consisted of immediate CP (early plasma group) versus no CP unless developing prespecified criteria of deterioration (deferred plasma group). Additional standard treatment was allowed in both arms. The primary outcome was a composite of mechanical ventilation, hospitalization for >14 days, or death. The key secondary outcomes included time to respiratory failure, days of mechanical ventilation, hospital length of stay, mortality at 30 days, and SARS-CoV-2 real-time PCR clearance rate. Of 58 randomized patients (mean age, 65.8 years; 50% male), 57 (98.3%) completed the trial. A total of 13 (43.3%) participants from the deferred group received plasma based on clinical aggravation. We failed to find benefit in the primary outcome (32.1% versus 33.3%, odds ratio [OR] 0.95, 95% CI 0.32-2.84, p > 0.999) in the early versus deferred CP group. The in-hospital mortality rate was 17.9% versus 6.7% (OR 3.04, 95% CI 0.54-17.17 p = 0.246), mechanical ventilation 17.9% versus 6.7% (OR 3.04, 95% CI 0.54-17.17, p = 0.246), and prolonged hospitalization 21.4% versus 30.0% (OR 0.64, 95% CI, 0.19-2.10, p = 0.554) in the early versus deferred CP group, respectively. The viral clearance rate on day 3 (26% versus 8%, p = 0.204) and day 7 (38% versus 19%, p = 0.374) did not differ between groups. Two patients experienced serious adverse events within 6 hours after plasma transfusion. The main limitation of this study is the lack of statistical power to detect a smaller but clinically relevant therapeutic effect of CP, as well as not having confirmed neutralizing antibodies in donor before plasma infusion.", "Conclusions", "In the present study, we failed to find evidence of benefit in mortality, length of hospitalization, or mechanical ventilation requirement by immediate addition of CP therapy in the early stages of COVID-19 compared to its use only in case of patient deterioration.
  • No Thumbnail Available
    Item
    Mutational Landscape and Actionable Target Rates on Advanced Stage Refractory Cancer Patients: A Multicenter Chilean Experience
    (2022) Cordova-Delgado, Miguel; Pinto, Mauricio P.; Regonesi, Carlos; Cereceda, Luis; Reyes, Jose Miguel; Itriago, Laura; Majlis, Alejandro; Rodriguez, Pablo; Fassler, Andre; Mahave, Mauricio; Leon, Maria Elisa; Gallardo, Jorge; Rodriguez, Maria Paz Z.; Berkovits, Alejandro; Manque, Patricio; Rios, Juvenal A.; Garcia-Bloj, Benjamin; Garrido, Marcelo
    Major advances in sequencing technologies and targeted therapies have accelerated the incorporation of oncology into the era of precision medicine and "biomarker-driven" treatments. However, the impact of this approach on the everyday clinic has yet to be determined. Most precision oncology reports are based on developed countries and usually involve metastatic, hard-to-treat or incurable cancer patients. Moreover, in many cases race and ethnicity in these studies is commonly unreported and real-world evidence in this topic is scarce. Herein, we report data from a total of 202 Chilean advanced stage refractory cancer patients. Retrospectively, we collected patient data from NGS tests and IHC in order to determine the proportion of patients that would benefit from targeted treatments. Overall >20 tumor types were included in our cohort and 37% of patients (n = 74) displayed potentially actionable alterations, including on-label, off-label and immune checkpoint inhibitor recommendations. Our findings were in-line with previous reports such as the cancer genome atlas (TCGA). To our knowledge, this is the first report of its kind in Latin America delivering real-world evidence to estimate the percentage of refractory tumor patients that might benefit from precision oncology. Although this approach is still in its infancy in Chile, we strongly encourage the implementation of mutational tumor boards in our country in order to provide more therapeutic options for advanced stage refractory patients.
  • Thumbnail Image
    Item
    Recomendaciones sobre el manejo del cáncer de páncreas tipo adenocarcinoma en Latinoamérica. Reunión del Consenso del Simposio Latinoamericano de Gastroenterología Oncológica (SLAGO) y de la Asociación Ibero Latinoamericana de Terapia Radiante (ALATRO), Viña del Mar, Chile 2015
    (2016) Caglevic, Christian; Gallardo, Jorge; De la Torre, Marcela; Mahave, Mauricio; Müller, Bettina; Solé, Sebastián; Moscoso, Yuri; De La Fuente, Hernán; Roa Strauch, Juan Carlos Enrique; Torres Montes, Paula Javiera